Category

Therapeutic Areas

Home > Therapeutic Areas (Page 32)

Rubio-Salvador, AR, Escudero-Vilaplana, V, Marcos Rodríguez, JA, Mangues-Bafalluy, I, Bernardez, B, García Collado, C, Collado-Borrell, R, Alvarado Fernández, M.D, Chacón López-Muñiz, JI, Yébenes Cortés, M, Gómez Barrera, M, Calleja-Hernández, MA

 

Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: Costecat Study
Int. J. Environ. Res. Public Health 2021, 18, 394

Colom J, Szerman N, Sabater E, Ferred F, Pascual F, Gilabert-Perramon A, Casado MA, Bobes J y Grupo de Trabajo MCDA-OUD

 

 

Estudio para la determinación de medidas de resultados en salud relevantes en el trastorno por consumo de opiáceos. Análisis de Decisión Multicriterio
Adicciones 2021; 33(2):109-119

Bastos-Oreiro M, Presa M, de las Heras A, Casado MA, Pardo C, Martín-Escudero V, Sureda A

 

 

Cost-effectiveness analysis of axicabtagene ciloleucel vs tisagenlecleucel for the management of diffuse large B-cell lymphoma in Spain
26th Congress of European Hematology Association (EHA). Virtual meeting. 9-17 jul 2021

Moltó J, González J, Navarro C, Presa M, Casado MA

 

 

Epidemiologic and economic analysis of targeted screening for human immunodeficiency virus in emergency department in Spain
Congress International Health Economics Association (IHEA). 12-15 jul 2021

Estrada V, Górgolas M, Peña JA, Tortajada E, Presa M, Casado MA

 

 

Epidemiologic and economic analysis of early antiretroviral therapy with bictegravir/embtricitabine/tenofovir alafenamide in Spain
Congress International Health Economics Association (IHEA). 12-15 jul 2021

Esteban R, Domínguez-Hernández R, Casado MA

 

 

 

Value assessment of sofosbuvir-based regimens for (chronic) hepatitis C in Spain
International Liver CongresssTM 2021 (ILC) (EASL). 23-26 jun 2021